Journal of Psychopharmacology

Article	Citations
Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat	201
The chronic effects of a combination of herbal extracts (Euphytose ® ) on psychological mood state and response to a laboratory stressor: A randomise	140
Off the RADAR; questions regarding the trial protocol of a randomised controlled trial of antipsychotic reduction and discontinuation	126
The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies	95
Science, safety and education: Informing the psychedelic treatment of psychiatric disorders	71
Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study	58
Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study	53
Psychedelics and the ‘inner healer’: Myth or mechanism?	52
The effects of the PDE4 inhibitor roflumilast on cognitive performance after a cerebrovascular accident: a double-blind randomized placebo-controlled trial with an open label extension (ROSTMEMA)	52
Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study	52
Preliminary evidence that serum interleukin-6 is a candidate biomarker of response to esketamine in treatment-resistant depression	51
Cannabimimetic and discriminative stimulus effects of hexahydrocannabinols in mice	51
Circadian rhythmicity in prepulse inhibition of the acoustic startle response: A study of chronotype and time-of-day effects in young healthy adults	48
Effects of initial nicotine exposure on cognition and nicotine reinforcement among non-smoking young adults with and without attention deficit hyperactivity disorder	47
Award winning abstracts presented at the 15 th Annual International College of Mental Health Pharmacy (CMHP) Conference, Liverpool, UK, on 10	47
Neurocognitive changes in lithium-treated older adult bipolar patients on antipsychotics	46
Co-use of psychedelics with other substances: Findings from the global psychedelic survey	44
Deaths related to the use of diarylethylamines, with a focus on the United Kingdom: A systematic review and case series report	43
Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment	41
Pharmaco-fUS in cognitive impairment: Lessons from a preclinical model	41
Relationship between change in social evaluation learning and mood in early antidepressant treatment: A prospective cohort study in primary care	39
Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration–effect relations using the IB-de-risk tool	38
An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine	37
Comparison of average time-to-relapse following ECT versus ketamine – A systematic review	36
The effects of antenatal depression and SSRI exposure on children: A systematic review	36

A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy	36
A framework for assessment of adverse events occurring in psychedelic-assisted therapies	35
The D1/D2-like receptor antagonist flupentixol and the D2-like receptor antagonist L-741626 decrease operant responding for nicotine and food and locomotor activity in male and female rats	34
Associations between regular cannabis use and brain resting-state functional connectivity in adolescents and adults	33
Dynamic excitatory-inhibitory differences in autistic and non-autistic adults: Evidence from a pharmacological challenge with arbaclofen	32
Psychedelic research – Going global	31
Voluntary nicotine consumption and reward in a subset of diversity outbred founder strains	30
Ketamine use in a large global sample: Characteristics, patterns of use and emergency medical treatment	30
Serotonin release by parachloroamphetamine in rats with high and low sociability: High prefrontal release capacity in sociable females	30
The 5-HT1A receptor biased agonists, NLX-204 and NLX-101, like ketamine, elicit rapid-acting antidepressant activity in the rat chronic mild stress model via cortical mechanisms	30
Corrigendum: Is psychedelic use associated with cancer? Interrogating a half-century-old claim using contemporary population-level data	29
Haloperidol dopamine receptor occupancy and antagonism correspond to delirium agitation scores and EPS risk: A PBPK-PD modeling analysis	28
Not too quick on “Debunking the myth of ‘Blue Mondays’”	28
The empathogen 3,4-methylenedioxymethamphetamine, but not methamphetamine, increases feelings of global trust	28
What are set and setting: Reducing vagueness to improve research and clinical practice	28
Every prescription is a prediction	27
The therapeutic readiness of probiotics in major depressive disorder: A systematic review of randomised controlled trials	27
Associations of antidepressants and antipsychotics with lipid parameters: Do CYP2C19 / CYP2D6 genes play a	26
Effects of LSD, DMT and psilocybin on cognitive and psychological functions: A systematic review of the literature	26
Mind the gap! Addressing unresolved aspects of abuse potential evaluation and scheduling of classic and novel psychedelic drugs	26
The New Zealand drug harms ranking study: A multi-criteria decision analysis	26
A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder	24
Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program	23
Wistar Kyoto rats exhibit decreased serotonin neuronal firing and increased norepinephrine burst activity but dampened hippocampal α 2 -adrenoceptor	23
Drug–drug interactions involving classic psychedelics: A systematic review	23
Psychedelic-assisted psychotherapy: The need to monitor adverse events	23
Statistical limitations of the claimed dose–response in “Dose–response efficacy and safety of lumateperone in bipolar depression: A preliminary meta-analysis of randomized controlled trials”	21
Ketamine/esketamine pharmacotherapy for treatment of anxiety disorders and anxiety symptoms in depression: Systematic review	21
The low risk for early renal damage during lithium treatment has not changed over time	21
The helioscope effect: A new framework for evaluating trauma-related memory processing in psychedelic experiences	21
Oxytocin prevents ketamine-induced executive control deficits in macaque monkeys	20
The goal of specificity in psychotropic drug development: A lesson from Sisyphus?	20
Antipsychotic co-medication and treatment response to rTMS and iTBS in depression: Data from clinical records from two independent clinical sites	20
Effect of CannEpil ® on simulated driving performance and co-monitoring of ocular activity: A randomised controlled trial	19
A randomised double-blind, placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression (the PAX-BD study)	19
A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression	19
The mechanism of action of clozapine	19
Cardiovascular mortality and depression: A systematic review and meta-analysis of the association with antidepressant treatment and co-morbidity	19
Impact of psychedelics on craving in addiction: A systematic review	19
Hippocampal phase precession is preserved under ketamine, but the range of precession across a theta cycle is reduced	18
Evaluation of the sedative-motor effects of novel GABAkine imidazodiazepines using quantitative observation techniques in rhesus monkeys	18
Association of clozapine treatment and rate of methamphetamine or amphetamine relapses and abstinence among individuals with concurrent schizophrenia spectrum and amphetamine use disorder: A retrospec	18
Evidence-based guidelines for the interpretation of the 9-item Concise Health Risk Tracking – Self-Report (CHRT-SR 9 ) measure of suicidal risk	18
Associations between paraoxonase-1 activity and therapeutic drug monitoring indicators in schizophrenia patients treated with olanzapine: A cross-sectional study	17
Eight-week antidepressant treatment effects on connectome gradient in first-episode drug-naïve patients with major depressive disorder	17
Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression	17
Validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview among outpatients with schizophrenia	16
Factor analysis of treatment acceptability in double-blind randomised clinical trial of home-based transcranial direct current stimulation in major depression and in healthy individuals	16
Associations between MDMA/ecstasy use and physical health in a U.S. population-based survey sample	16
Psilocybin for clinical indications: A scoping review	16

The effects of reserpine on depression: A systematic review	16
Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors	16
Escitalopram and functional connectivity in major depressive disorder: A systematic review	16
Negative affect interacts with perceptual affective biases	15
Blackcurrant ( Ribes nigrum L.) improves cholinergic signaling and protects against chronic Scopolamine-induced memory impairment in mice	15
Efficacy and safety of pharmacological and non-pharmacological interventions for antipsychotic-induced weight gain in individuals with schizophrenia: A systematic review and network meta-analysis of 5	15
The impact of antidepressant use on MDMA fatalities: A matched case-control study using a post-mortem database	15
Predictors of therapeutic response to psychedelic-assisted therapy: A systematic review	15
Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research	14
Is lack of goal-conflict-specific rhythmicity a biomarker for treatment resistance in generalised anxiety but not social anxiety or major depression?	14
Pivotal role of orexin signaling in the posterior paraventricular nucleus of the thalamus during the stress-induced reinstatement of oxycodone-seeking behavior	14
Examining the role of systemic chronic inflammation in diet and sleep relationship	14
Modafinil: A closer look at its theoretical toxicological potential	14
Subjectively reported sleep improvement with antipsychotic medications in clinical practice: A systematic review, meta-analysis and meta-regression of moderating factors	13
Exploring the efficacy and safety of a novel standardized ashwagandha ( Withania somnifera ) root extract (Witholytin®) in adults experiencing high stres	13
Mechanisms of psilocybin on the treatment of posttraumatic stress disorder	13
Effects of cannabidiol on behavioral and psychological symptoms of vascular dementia: A randomized, double-blind, placebo-controlled clinical trial	13
Chronic Cannabis users exhibit altered oscillatory dynamics and functional connectivity serving visuospatial processing	13
Assessment of the reporting of harms in systematic reviews focused on hallucinogens: A cross-sectional study	13
A three-stage strategy for conducting an experimental investigation: A recommendation to improve the reproducibility of reported conclusions	13
Older adults in psychedelic-assisted therapy trials: A systematic review	13
Effects of psilocybin on personality, psychiatric symptoms, and values: Exploring mediating effects of the acute psychedelic experience	12
The CannTeen Study: Cannabis use disorder, depression, anxiety, and psychotic-like symptoms in adolescent and adult cannabis users and age-matched controls	12
Amphetamine use disorder is associated with striatum hypoactivation during anticipation of loss and reward	12
Risk of major congenital malformations and heart defects in pregnancies exposed to first-trimester drugs for depression and co-medications	12
We need to talk: The urgent conversation on chronic pain, mental health, prescribing patterns and the opioid crisis	12
Just a gut feeling: Faecal microbiota transplant for treatment of depression – A mini-review	12
The role of psychopharmacology and cognitive neuroscience in understanding the brain in the treatment of psychiatric disorders and neurological diseases for the benefit of society	12
Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD)	12
Revisiting monoamine oxidase inhibitors: A potential dual-action therapy for patients with prostate cancer and comorbid depression?	12
Episodic foresight is impaired following acute alcohol intoxication	12
A systematic review of the pharmacokinetics of classical serotonergic psychedelic compounds in healthy adult subjects	11
Concomitant use of antidepressants and classic psychedelics: A scoping review	11
The psychedelic effects of cannabis: A review of the literature	11
The association between N -methyl- d -aspartate receptor availability and glutamate levels: A multi-mo	11
Significance of mammalian N, N-dimethyltryptamine (DMT): A 60-year-old debate	11
Temporal profile of intranasal oxytocin in the human autonomic nervous system at rest: An electrocardiography and pupillometry study	11
Common protein networks for various drug regimens of major depression are associated with complement and immunity	11
Younger, drunk, and fast: Paradoxical rapid reaction time in hazardous drinkers	11
Predicting and exploring ayahuasca effects: Perception, mind-wandering, and EEG oscillations	11
Pictorial representation of illness and self measure (PRISM): A putative transdiagnostic tool for evaluating therapeutic effects of psychedelic treatments	11
A randomized, double-blind, placebo-controlled, Phase 1 study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of an immediate-release oral ketamine capsule in healthy vo	11
Recasting the role of electroconvulsive therapy and the electroconvulsive therapy practitioner: For severe illness, not necessarily treatment-resistant depression	11
Effects of CYP2D6*4 polymorphism on the steady-state concentration of paroxetine in patients diagnosed with depressive episode and comorbid alcohol use d	10
A transdiagnostic systematic review and meta-analysis of ketamine’s anxiolytic effects	10
Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth	10
Long-term neurocognitive side effects of MDMA in recreational ecstasy users following sustained abstinence: A systematic review and meta-analysis	10
Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression	10
OAV and 5D-ASC for Brazilian Portuguese: A validation and adaptation study	10
Sub-anesthetic doses of ketamine increase single cell entrainment in the rat auditory cortex during auditory steady-state response	10
Intracerebroventricular knockdown of NPY1R disrupts NPY1R-GALR2/TrkB heteroreceptor complexes without affecting neuroplasticity or depressive-like behaviour	10
No evidence that post-training dopamine D2 receptor agonism affects fear generalization in male rats	9
Tripping into the unknown: Exploring the experiences of first-time LSD users through global drug survey insights	9
Hippocampal and parahippocampal volume and function predict antidepressant response in patients with major depression: A multimodal neuroimaging study	9
Causes, clinical characteristics, and outcomes of high lithium levels and intoxications: Retrospective analysis of patient records	9
Landscape analysis of pre-registered clinical trials involving classical psychedelics	9
The interaction between kynurenine pathway, suicidal ideation and augmentation therapy with minocycline in patients with treatment-resistant depression	9
Role of chemokines in depression: Highlights on CX 3 CL1/CX 3 CR1 signaling	9
Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database	9
Self-treatment of psychiatric conditions using ketamine: Patterns, characteristics, and retrospective insights	9
Is there a risk of addiction to ketamine during the treatment of depression? A systematic review of available literature	9
Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis	8
Hemispheric annealing and lateralization under psychedelics (HEALS): A novel hypothesis of psychedelic action in the brain	8
Escitalopram should be investigated in anorexia nervosa: Rationale and review of mechanisms	8
Prenatal THC exposure and binge-like alcohol drinking in early adolescence: From sex-specific drinking vulnerability to abnormal endocannabinoid-dopamine nexus in the nucleus accumbens	8
Clinical correlates of early onset antipsychotic treatment resistance	8
Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020	8
Common pitfalls, and how to avoid them, in child and adolescent psychopharmacology: Part I	8
Interactions of alcohol and the benzodiazepine inverse agonist in healthy male volunteers	8
Role of serotonin in modulation of decision-making in Parkinson’s disease	8
Trip killers: Addressing a critical knowledge gap in psychedelic research	8
Effects of acute lysergic acid diethylamide on intermittent ethanol and sucrose drinking and intracranial self-stimulation in C57BL/6 mice	8
Increasing recreational nitrous oxide use: Should we worry? A narrative review	8
Mapping acute alcohol effects on bodily sensations: A cross-dimensional interoceptive approach	8
Ketamine: A new chapter for clinical psychopharmacology?	8
Targeting disrupted networks in schizophrenia: Can muscarinic drugs make a fundamental difference?	8
Exploring the impact of MDMA and oxytocin ligands on anxiety and social responses: A comprehensive behavioural and molecular study in the zebrafish model	8
Psilocybin history, action and reaction: A narrative clinical review	7
Modification of natural tryptamines for the treatment of neuropsychiatric diseases	7
Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview	7

Appraisal of the validity of preclinical investigations to predict the efficacy of psychedelic drugs as fast-acting antidepressants	7
Role of α1-GABA A receptors in the serotonergic dorsal raphe nucleus in models of opioid reward, anxiety, and depression	7
Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review	7
Effect of ashwagandha ( Withania somnifera ) extract with Sominone (Somin-On™) to improve memory in adults with mild cognitive impairment: A randomized,	7
“Too small to succeed?” Rethinking efficacy claims in a solriamfetol trial for ME/CFS	7
Development of the Protective Strategies for Psychedelics Scale: A novel inventory to assess safety strategies in the context of psychedelics	7
An exploration of the relationships between the effects of psilocybin on behavior, 5-HT 2A receptor occupancy, and neuroplastic effects in mice	7
The efficacy of vortioxetine in the acute treatment of major depressive disorder: A systematic review and meta-analysis	7
Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression	7
Naturalistic use of psychedelics is associated with longitudinal improvements in anxiety and depression during global crisis times	7
Co-medication with disulfiram markedly increased serum clozapine levels: Two case reports	7
Monoamine neurotransmitter-related gene-based genome-wide association study of low-dose ketamine in patients with treatment-resistant depression	7
Roland R. Griffiths, psychopharmacology pioneer: Abuse liability, alcohol, nicotine, caffeine, benzodiazepines, and psychedelics	7
Award winning abstracts presented at the 14 th Annual International College of Mental Health Pharmacy (CMHP) Conference Glasgow, UK, on 11	6
Higher orexin-A levels are associated with treatment response to clozapine in patients with schizophrenia: A cross-sectional study	6
Metformin efficacy and safety as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled trial	6
From monotherapy to sequential models: An updated scoping review on ibogaine’s role in treatment for psychiatric disorders	6
Nucleus accumbens serotonin 1A receptor expression is altered by female reproduction and regulates postpartum affective and caregiving behaviors	6
Efficacy and adverse effect profile of vortioxetine in major depressive disorder: A meta-analysis	6
A systematic review and narrative summary of the therapeutic potential of classic serotonergic psychedelics for smoking cessation and reduction	6
Characteristics of poisonings involving ketamine in the United States, 2019–2021	6
Influence of panic disorder and paroxetine on brain functional hubs in drug-free patients	6
Harnessing placebo: Lessons from psychedelic science	6
Roles of the 5-HT1A receptor in zebrafish responses to potential threat and in sociality	6
β -blockers’ neuropsychiatric risks: Overlooked evidence?	6
Influence of GABA A and GABA B receptor activation on auditory sensory gating and its association	6
Severe neutropenia unrelated to clozapine in patients receiving clozapine	6
Commentary on Cochrane review: “Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder”	6
Impact of patient-specific factors on clozapine metabolism in individuals with treatment-resistant schizophrenia or schizoaffective disorder	6
Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers’ task group on psychedelics and related compoun	6
Boosting the ventrolateral periaqueductal gray-ventral tegmental area pathway by disinhibition of group II mGluRs alleviates chronic restraint stress-induced depression-like behavior in mice	6
Fluoxetine rescues the depressive-like behaviour induced by reserpine and the altered emotional behaviour induced by nicotine withdrawal in zebrafish: Involvement of tyrosine hydroxylase	6
Mechanistic insights into the safety of daridorexant in older adults: From postural stability to next-day function	5
Effects of gamma-aminobutyric acid on working memory and attention: A randomized, double-blinded, placebo-controlled, crossover trial	5
A meta-analysis of potential genetic factors associated with antipsychotic-induced weight gain in adults with severe mental illness	5
Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response	5
Facing trauma under the influence of psychedelics: A phenomenological study with Nova rave survivors	5
Habitual caffeine intake, genetics and cognitive performance	5
Catalyst for change: Psilocybin’s antidepressant mechanisms—A systematic review	5
Clozapine rechallenge or continuation despite neutropenia or agranulocytosis using colony-stimulating factor: A systematic review	5
Long-read sequencing of CYP2D6 may improve psychotropic prescribing and treatment outcomes: A systematic review and meta-analysis	5
Associations between psychedelic use and migraine history in Swedish twins	5
Exploring clozapine use in severe psychiatric symptoms associated with autism spectrum disorder: A scoping review	5
Impaired face symmetry detection under alcohol, but no ‘beer goggles’ effect	5
Effects of ketamine enantiomers on morphine and THC subjective effects in rats	5
Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study	5
Cell-based serum anticholinergic activity assay and working memory in cognitively healthy older adults before and after scopolamine: An exploratory study	5
MDMA enhances positive affective responses to social feedback	5
Associations of treatment with hypnotics with suicide and attempted suicide: A nationwide cohort study	5
Reduced attentional lapses in male rats following a combination treatment of low-dose D-serine and atomoxetine	5
Comparative efficacy of quetiapine by dose and formulation for psychosis in schizophrenia: A systematic review and dose–response model-based network meta-analysis	5
Antipsychotic polypharmacy and high-dose antipsychotic therapy compared to antipsychotic monotherapy at standard doses in schizophrenia – a systematic review	5
Speech markers of psychological change following a psychedelic 5-MeO-DMT retreat	5
Antipsychotic action and symptom specificity – down the bioinformatic rabbit hole	5
Pharmacokinetics and pharmacodynamics of sublingual microdosed lysergic acid diethylamide in healthy adult volunteers	5
Abuse potential assessment of the dual orexin receptor antagonist daridorexant in rats	5
Six weeks open-label oral ketamine for patients with treatment-resistant depression, post-traumatic stress disorder, or obsessive-compulsive disorder	5
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease	5
Adolescent substance use trajectories are associated with nucleus accumbens functional connectivity	5
The pseudoscience of lithium and suicide: Reanalysis of a misleading meta-analysis	5
Individual differences in cocaine-induced conditioned place preference in male rats: Behavioral and transcriptomic evidence	5
Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics	5
Classic psychedelics and personality: An updated systematic review	4
Can cannabinoids alleviate behavioral symptoms in older adults with dementia? A systematic review	4
Ketamine-induced changes in resting state connectivity, 2 h after the drug administration in patients with remitted depression	4
The impact of cannabidiol placebo on amygdala-based neural responses to an acute stressor	4
Psychiatric risks for worsened mental health after psychedelic use	4
Antidepressant initiation and the risk of treatment-emergent mania in children and adolescents with depression: A real-world cohort study	4
Repeated administration of L-alanine to mice reduces behavioural despair and increases hippocampal mammalian target of rapamycin signalling: Analysis of gender and metabolic effects	4
Hyperdopaminergia in rats is associated with reverse effort-cost dependent performance	4
Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes	4
Ketamine for refractory depression: Save the best for last?	4
Enhancement of memory network activity in schizophrenia patients by phosphodiesterase-4 (PDE4) inhibitor, roflumilast: A pilot study	4
Peri-traumatic consumption of classic psychedelics is associated with lower anxiety and post-traumatic responses 3 weeks after exposure	4
Rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine in a real-world, psychedelic paradigm	4
Low-frequency monitoring for community clozapine initiations: A comparative study relative to standard frequency assessments	4
Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers	4
Predicting clozapine dose required to achieve a therapeutic plasma concentration – A comparison of a population algorithm and three algorithms based on gene variant models	4
Esketamine nasal spray for treatment-resistant depression: A retrospective multicenter real-world cohort study on effectiveness and suicidal outcomes	4
Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial	4
The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients	4
Oral sodium oxybate does not alter plasma kisspeptin levels in healthy male volunteers	4
CYP1A2 genotype-dependent effects of smoking on mirtazapine serum concentrations	4
The relationship between Parkinson’s disease and sexual hyperactivity secondary to drug treatment: A systematic review	4
Association of polygenic risk for cannabis use disorder with brain structure among youth with and without bipolar disorder	4
Fluoroquinolones and risk of nightmares: A literature review and disproportionality analysis using individual case safety reports from Food and Drug Administration Adverse Event Reporting System datab	4
Less is more? A review of psilocybin microdosing	4
The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics	4
Compassionate use of esketamine intranasal in patients with severe major depressive disorder resistant to the treatment	4
Confronting mortality: A meta-analysis and systematic review of psychedelic experiences and death anxiety	4
Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review	4
Impact of childhood adversity on acute subjective effects of stimulant and opioid drugs: Evidence from placebo-controlled studies in healthy volunteers	4
A phase 1 randomized, placebo-controlled study to investigate potential interactions between ASP8062, a positive allosteric modulator of the GABA B r	4
Clinical effects of CYP2D6 phenoconversion in patients with psychosis	4
Award winning abstracts presented at the 12th Annual International College of Mental Health Pharmacy (CMHP) Conference, Northampton, UK on 7th and 8th October 2022	4